Atezolizumab plus bevacizumab (A plus B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function

被引：0
|
作者：
Storandt, Michael H.
Zemla, Tyler J.
Patell, Kanchi
Naleid, Nikolas
Gile, Jennifer
Tran, Nguyen H.
Chakrabarti, Sakti
Jin, Zhaohui
Mahipal, Amit
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[3] Univ Hosp Cleveland Med Ctr, Dept Internal Med, Cleveland, OH USA
[4] Mayo Clin, Div Med Oncol, Rochester, MN USA
[5] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[6] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Dept Oncol, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4099
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib
    Chihiro, Kikukawa
    Kawaoka, Tomokazu
    Uchikawa, Shinsuke
    Kinami, Takahiro
    Yamasaki, Shintaro
    Kosaka, Masanari
    Johira, Yusuke
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Yamaoka, Kenji
    Teraoka, Yuji
    Uchida, Takuro
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Miki, Daiki
    Tsuge, Masataka
    Imamura, Michio
    Aikata, Hiroshi
    Oka, Shiro
    ONCOLOGY, 2023, 101 (08) : 491 - 501
  • [32] Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma
    Kobayashi, Kojiro
    Nagai, Hidenari
    Matsui, Teppei
    Matsuda, Takahisa
    Higai, Koji
    ANTICANCER RESEARCH, 2023, 43 (10) : 4601 - 4609
  • [33] Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy
    Fulgenzi, C.
    D'Alessio, A.
    Scheiner, B.
    Ang, C.
    Wietharn, B.
    Pinter, M.
    Nishida, N.
    Parisi, A.
    Huang, Y.
    Bettinger, D.
    Vogel, A.
    Silletta, M.
    Schoenlein, M.
    Galle, P.
    Kudo, M.
    Singal, A.
    Cortellini, A.
    Chon, H.
    Stefanini, B.
    Giannini, E.
    Pinato, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S7 - S7
  • [34] COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
    Boonkaya, Sangdao
    Thanapirom, Kessarin
    Siripon, Nipaporn
    Thaimai, Panarat
    Ananchuensook, Prooksa
    Sriphoosanaphan, Supachaya
    Tanasanvimon, Surbpong
    Treeprasertsuk, Sombat
    Komolmit, Piyawat
    GASTROENTEROLOGY, 2024, 166 (05) : S73 - S74
  • [35] A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma
    Doshi, Sahil D.
    Dizman, Nazli
    Knezevic, Andrea
    Touma, Amina
    Alaghehbandan, Reza
    Ged, Yasser
    Ornstein, Moshe Chaim
    Hahn, Andrew Warren
    Msaouel, Pavlos
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Niizeki, Takashi
    Tokunaga, Takayuki
    Takami, Yuko
    Wada, Yoshiyuki
    Harada, Masaru
    Shibata, Michihiko
    Nakao, Kazuhiko
    Sasaki, Ryu
    Hirai, Fumihito
    Shakado, Satoshi
    Yoshizumi, Tomoharu
    Itoh, Shinji
    Yatsuhashi, Hiroshi
    Bekki, Shigemune
    Ido, Akio
    Mawatari, Seiichi
    Honda, Koichi
    Sugimoto, Rie
    Senju, Takeshi
    Takahashi, Hirokazu
    Kuwashiro, Takuya
    Maeshiro, Tatsuji
    Nakamuta, Makoto
    Aratake, Yoshifusa
    Yamashita, Tsutomu
    Otsuka, Yuichiro
    Matsumoto, Shuichi
    Sohda, Tetsuro
    Shimose, Shigeo
    Murotani, Kenta
    Tanaka, Yasuhito
    TARGETED ONCOLOGY, 2022, 17 (06) : 643 - 653
  • [37] Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Takashi Niizeki
    Takayuki Tokunaga
    Yuko Takami
    Yoshiyuki Wada
    Masaru Harada
    Michihiko Shibata
    Kazuhiko Nakao
    Ryu Sasaki
    Fumihito Hirai
    Satoshi Shakado
    Tomoharu Yoshizumi
    Shinji Itoh
    Hiroshi Yatsuhashi
    Shigemune Bekki
    Akio Ido
    Seiichi Mawatari
    Koichi Honda
    Rie Sugimoto
    Takeshi Senju
    Hirokazu Takahashi
    Takuya Kuwashiro
    Tatsuji Maeshiro
    Makoto Nakamuta
    Yoshifusa Aratake
    Tsutomu Yamashita
    Yuichiro Otsuka
    Shuichi Matsumoto
    Tetsuro Sohda
    Shigeo Shimose
    Kenta Murotani
    Yasuhito Tanaka
    Targeted Oncology, 2022, 17 : 643 - 653
  • [38] Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
    Hou, Yanli
    Wu, Bin
    CANCER COMMUNICATIONS, 2020, 40 (12) : 743 - 745
  • [39] The impact of previous local therapy (LT) on overall survival (OS) in patients with advanced hepatocellular carcinoma (aHCC) treated with atezolizumab/bevacizumab (A plus B) as first line systemic therapy
    Fierro, Maria Elena
    Alkadimi, Munaf
    Boyle, Lauren Diaz
    Lucero, Kana
    Mader, Michael
    Franklin, Kathleen
    Nooruddin, Zohra
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Real-world experience with atezolizumab plus bevacizumab in the management of nonresectable hepatocellular carcinoma refractory to first-line systemic therapy: Review of literature.
    Devarkonda, Vishal
    Byreddi, Laxman Yashwant
    Balmuri, Shravya
    Gudi, Thulasi
    Gaddam, Shiva Jashwanth
    Keerty, Dinesh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345